Recent News

• 04.22.2025 - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
• 04.16.2025 - Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
• 04.15.2025 - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
• 04.11.2025 - Scilex Holding Company Announces 1-for-35 Reverse Stock Split
• 03.27.2025 - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
• 03.10.2025 - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Recent Filings

• 04.22.2025 - EX-99.1 EX-99.1
• 04.22.2025 - 8-K Current report
• 04.21.2025 - 8-K Current report
• 04.15.2025 - 8-K Current report
• 04.11.2025 - EX-99.1 EX-99.1
• 04.11.2025 - 8-K Current report
• 04.01.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.20.2025 - 8-K Current report
• 03.20.2025 - 424B3 Prospectus [Rule 424(b)(3)]